Lawrence Blatt, Aligos CEO
March 22, 2022 10:45 AM EDTUpdated 03:49 PM
R&D

Ali­gos chops off a he­pati­tis B pro­gram — again — af­ter a pa­tient was briefly hos­pi­tal­ized

Max Gelman

Senior Editor

Ali­gos is fac­ing an­oth­er set­back af­ter a Phase I study missed the mark and re­vealed safe­ty is­sues for an an­ti­sense chron­ic he­pati­tis B pro­gram. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

A service from the Financial Times